Rhythm Pharmaceuticals (RYTM) Stock Statistics & Valuation Metrics

Rhythm Pharmaceuticals has a market cap or net worth of $6.48B. The enterprise value is $3.99B.

Rhythm Pharmaceuticals has 66,420,090 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rhythm Pharmaceuticals’s return on equity (ROE) is -1.58 and return on invested capital (ROIC) is -96.06%.

The current PE Ratio of Rhythm Pharmaceuticals is ―. Rhythm Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.60M in profits. Earnings per share was -4.21.

In the last 12 months, operating cash flow was -107.72M and capital expenditures 40.00M, giving a free cash flow of -67.72M billion.

Rhythm Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rhythm Pharmaceuticals upcoming earnings date is Nov 11, 2025, TBA (Confirmed).

Rhythm Pharmaceuticals as a current ratio of 3.24, with Debt / Equity ratio of 3.14%

In the past 12 months, Rhythm Pharmaceuticals has paid 346.00K in taxes.

Rhythm Pharmaceuticals EV to EBITDA ratio is -13.98, with an EV/FCF ratio of -29.24.

Rhythm Pharmaceuticals has $291.03M in cash and marketable securities with $4.19M in debt, giving a net cash position of -$286.84M billion.

Gross margin is 89.25%, with operating margin of -204.04%, and net profit margin of -200.27%.

The average price target for Rhythm Pharmaceuticals is $108.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy